- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
18 result(s) found for: Labial.
Displaying page 1 of 1.
EudraCT Number: 2011-002135-26 | Sponsor Protocol Number: 4PH/2011/002 | Start Date*: 2012-02-16 | |||||||||||
Sponsor Name:AESCULAPIUS FARMACEUTICI S.R.L. | |||||||||||||
Full Title: Efficacy and Safety of Acyclovir 5 Lipstick (Contra) in Treatment of Skin Infections Provoked by Herpes Simplex. A Randomised, Double-blind, Placebo Controlled, Parallel Group Study. | |||||||||||||
Medical condition: History of recurrent herpes labialis with at least 3 recurrences during the past 12 months and typically (>50% of episodes) associated with prodromal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004015-21 | Sponsor Protocol Number: CA-P-3978-01 | Start Date*: 2006-08-31 | |||||||||||
Sponsor Name:Johnson & Johnson Consumer and Personal Products Worldwide | |||||||||||||
Full Title: Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis | |||||||||||||
Medical condition: Herpes Labialis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021144-17 | Sponsor Protocol Number: EA10-01-998 | Start Date*: 2011-01-12 | |||||||||||
Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: A phase III, multi-center, double-blind, randomized, vehicle controlled trial in a parallel-group design to evaluate the efficacy and safety of two formulations of Muxan containing 0.5 % or 1 % chl... | |||||||||||||
Medical condition: Male or female patients, aged 12 years or older (first part of the trial: only patients aged 18 years or older), with an adequate history of recurrent herpes labialis and an acute episode of herpes... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004316-31 | Sponsor Protocol Number: FPP4-DE-401 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:Novartis Consumer Health S.A. | |||||||||||||
Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ... | |||||||||||||
Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002213-13 | Sponsor Protocol Number: 6 BT | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:Menarini Ricerche S.p.A. | |||||||||||||
Full Title: A Phase I/II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Systemic Absorption and Dihydropyrimidine Dehydrogenase (DPD) Enzyme Activity Following Re... | |||||||||||||
Medical condition: Herpes Simplex Labialis (HSL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000926-24 | Sponsor Protocol Number: HTX101-03L | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Heidelberg ImmunoTherapeutics | ||||||||||||||||||
Full Title: A Randomised, Double-Blind Phase II Trial of Topical HDIT101 versus Placebo in Patients with Chronic Recurrent HSV-1 Infection and Orolabial Lesion | ||||||||||||||||||
Medical condition: Chronic Herpes Simplex Virus-1 Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003131-31 | Sponsor Protocol Number: M19-956 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren’s Syndrome. | |||||||||||||
Medical condition: Moderately to Severely Active Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020538-24 | Sponsor Protocol Number: GASAS-1002X | Start Date*: 2011-02-16 |
Sponsor Name:GABA International AG | ||
Full Title: White spot lesion development in post-orthodontic patients following weekly application of a 1.25% fluoride gel compared to placebo over 6 months | ||
Medical condition: To monitor the white spot lesion development and dental status under weekly applied 1.25% fluoride gel compared to placebo in patients after orthodontic treatment with multibracket appliances | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005788-24 | Sponsor Protocol Number: BA2005/21/02 | Start Date*: 2007-02-15 |
Sponsor Name:Bioalliance Pharma | ||
Full Title: A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo... | ||
Medical condition: Herpes labialis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) FR (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000791-29 | Sponsor Protocol Number: CICLO-LPO | Start Date*: 2017-07-13 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cyclosporine mucoadhesive gel at two different concentrations in the topical treatment of lichen planus in ... | |||||||||||||
Medical condition: oral lichen planus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004457-10 | Sponsor Protocol Number: PS0104 | Start Date*: 2006-01-16 | |||||||||||
Sponsor Name:Laboratoires Expanscience | |||||||||||||
Full Title: Clinical and biological activity of Piascledine® 300 in patients with chronic periodontitis | |||||||||||||
Medical condition: CHRONIC PERIODONTITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021430-64 | Sponsor Protocol Number: RR10/9389 | Start Date*: 2010-12-03 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. | |||||||||||||
Medical condition: Primary Sjögren’s syndrome (PSS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005555-80 | Sponsor Protocol Number: V00400SB302 | Start Date*: 2015-05-21 | |||||||||||
Sponsor Name:Pierre Fabre Dermatologie represented by IRPF | |||||||||||||
Full Title: Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study | |||||||||||||
Medical condition: High risk infantile haemangioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000665-32 | Sponsor Protocol Number: 80202135SJS2001 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) PT (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006017-41 | Sponsor Protocol Number: XER-002 | Start Date*: 2006-03-28 | |||||||||||
Sponsor Name:Calabar AB | |||||||||||||
Full Title: A single-centre, placebo-controlled, cross-over, double blind study of the effects on salivation by increasing doses of physostigmine applied to the labial mucosa of subjects with chronic dry mouth... | |||||||||||||
Medical condition: Chronic dry mouth | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005055-20 | Sponsor Protocol Number: CVAY736A2103 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, non-randomized, biopsy-based mechanistic study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome | |||||||||||||
Medical condition: Sjögren's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004476-30 | Sponsor Protocol Number: BP30037 | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME | |||||||||||||
Medical condition: Primary Sjögren’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) DE (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001948-19 | Sponsor Protocol Number: IM101-603 | Start Date*: 2017-02-02 | |||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome | |||||||||||||||||||||||||||||||||
Medical condition: Adults with moderately to severely Active Primary Sjögrens Syndrome | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
